Comparative Pharmacology
Head-to-head clinical analysis: DEPEN versus PENTETATE CALCIUM TRISODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPEN versus PENTETATE CALCIUM TRISODIUM.
DEPEN vs PENTETATE CALCIUM TRISODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillamine is a chelating agent that forms soluble complexes with heavy metals (e.g., copper, mercury, lead) and promotes their renal excretion. In rheumatoid arthritis, it reduces rheumatoid factor and immune complexes, and inhibits collagen cross-linking.
Pentetate calcium trisodium is a chelating agent that forms stable complexes with divalent and trivalent heavy metal ions, such as plutonium, americium, and curium. It enhances the urinary elimination of these metals by increasing the rate of dissociation from tissues and promoting renal excretion.
250 mg orally 4 times daily, target dose 1000-1500 mg/day in divided doses.
1 g (one vial) intravenously over 1 hour once daily for up to 5 days.
None Documented
None Documented
1.5-4 hours; prolonged to 6-12 hours in renal impairment; clinical context: dosing interval adjustments needed in CKD.
Terminal elimination half-life is approximately 0.6-0.8 hours in patients with normal renal function.
Renal: 50% as unchanged drug; biliary/fecal: minor, <5%.
Primarily renal elimination via glomerular filtration; >90% of absorbed dose excreted unchanged in urine within 24 hours.
Category C
Category C
Chelating Agent
Chelating Agent